Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Aug 2016 Planned End Date changed from 1 Mar 2020 to 1 Jul 2017.
- 01 Aug 2016 Status changed from recruiting to discontinued.
- 30 Mar 2015 Planned End Date changed from 1 Dec 2016 to 1 Mar 2020 as reported by ClinicalTrials.gov record.